Briefing From The Editor — ELAN Stock

Mid-cap Healthcare company Elanco Animal Health has moved -1.1% so far today on a volume of 3,853,358, compared to its average of 7,009,767. In contrast, the S&P 500 index moved 0.4%.

Elanco Animal Health trades -25.0% away from its average analyst target price of $17.44 per share. The 9 analysts following the stock have set target prices ranging from $12 to $23, and on average have given Elanco Animal Health a rating of hold.

If you are considering an investment in ELAN, you'll want to know the following:

  • Elanco Animal Health has moved -51.2% over the last year, and the S&P 500 logged a change of -12.6%

  • Based on its trailing earnings per share of -0.75, Elanco Animal Health has a trailing 12 month Price to Earnings (P/E) ratio of -17.5 while the S&P 500 average is 15.97

  • ELAN has a forward P/E ratio of 12.8 based on its forward 12 month price to earnings (EPS) of $1.02 per share

  • The company has a price to earnings growth (PEG) ratio of 1.4 — a number near or below 1 signifying that Elanco Animal Health is fairly valued compared to its estimated growth potential

  • Its Price to Book (P/B) ratio is 0.9 compared to its sector average of 4.07

  • Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals.

  • Based in Greenfield, the company has 9,000 full time employees and a market cap of $6,202,601,472.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.